Brigatinib was effective in TKI-naive patients with ROS1-rearranged NSCLC. The safety profile of brigatinib was consistent with that reported from previous studies.
Keyphrases
- phase ii study
- cell death
- dna damage
- advanced non small cell lung cancer
- reactive oxygen species
- small cell lung cancer
- open label
- locally advanced
- hiv infected
- squamous cell carcinoma
- randomized controlled trial
- clinical trial
- oxidative stress
- case control
- brain metastases
- epidermal growth factor receptor
- antiretroviral therapy